DR. MANOJ K. EAPEN, M.D.

Plain English
This study looked at a man in his 60s with diabetes who developed painful swellings and pus-filled infections at his insulin injection sites over 10 months. The infections were caused by non-tuberculous mycobacteria (NTM), which were identified through lab tests. After treatment with two antibiotics, his condition improved significantly over five months. Who this helps: This information is valuable for patients with diabetes who use insulin, as well as doctors treating them.

Plain English
This study looked at a new treatment called risto-cel for patients with sickle cell disease, a condition that causes severe pain and anemia due to sickle-shaped red blood cells. The researchers found that, after treatment, 13 patients showed high levels of healthy fetal hemoglobin (over 60% of their total hemoglobin) and very low levels of sickle hemoglobin (less than 40%). Importantly, no severe pain crises occurred after 60 days post-treatment, suggesting risto-cel could effectively help reduce the symptoms of sickle cell disease. Who this helps: Patients with sickle cell disease can benefit significantly from this treatment.

Plain English
This study focuses on how gene therapy can be used to treat sickle cell disease (SCD). It highlights new guidelines for doctors on how to choose the right patients for treatment and ensure their safety and well-being during and after the process. By creating standardized recommendations, such as assessing eligibility and providing psychosocial support, the aim is to make gene therapy safer and more accessible for patients. Who this helps: This helps patients with sickle cell disease and their healthcare providers.

Plain English
This study looked at two unusual cases of mixed neuroendocrine non-neuroendocrine tumors (MINEN) in the liver, adding to a total of 33 reported cases in medical literature. Both patients were diagnosed during tests for other issues, and while their liver function tests were mostly normal, a specific protein level was higher, which helped in diagnosis. One patient had surgery, and the other received a liver transplant; both have shown cancer spread but are still alive after 12-15 months, highlighting the poor outlook often associated with this type of tumor. Who this helps: This information benefits doctors and researchers working on liver tumors, helping them to understand and treat patients with similar conditions better.

Plain English
This study looked at the effectiveness of hematopoietic cell transplantation (HCT) compared to standard care for adolescents and young adults with sickle cell disease. Researchers found that after two years, 89% of those who received a transplant were alive, compared to 93% of those who did not have a donor. The transplant group experienced fewer pain crises and reported less fatigue, along with a better ability to engage in social activities. Who this helps: This benefits adolescents and young adults with sickle cell disease, offering them an option for better health outcomes.

Plain English
This study looked at a type of bone marrow transplant using related donors for adults with sickle cell disease to see if it could effectively treat the condition. Out of 54 participants, 42 received the transplant, and two years later, 88% were free from complications related to the disease while 95% were still alive. This is important because it shows that this method could be a promising treatment option for adults suffering from sickle cell disease, despite some risks of complications. Who this helps: This benefits adults with sickle cell disease seeking effective treatment options.

Plain English
This research compared two systems used to assess the risk of recurring thyroid cancer in patients in India. It analyzed data from 221 patients and found that when using the newer 2015 guidelines, only 9.4% of patients changed their risk category, and both systems provided similar predictions for treatment outcomes over time. This is important because it means that the older 2009 guidelines can still be reliably used in places where detailed medical reports aren't available. Who this helps: This helps doctors treating thyroid cancer patients in resource-limited settings.

Plain English
This study looked at how well a new treatment called BromAc works with collagenase to break down hard mucin in patients with a rare cancer called pseudomyxoma peritonei (PMP). The researchers found that when they added collagenase, almost 100% of the hard mucin dissolved after 24 hours, with the best results seen at 250 micrograms per milliliter. This matters because it could improve treatment for patients with PMP who have tough mucin that traditional therapies struggle to dissolve. Who this helps: This helps patients with pseudomyxoma peritonei.

Plain English
This study looked at 47 children diagnosed with childhood absence epilepsy (CAE) to check how many also had attention-deficit/hyperactivity disorder (ADHD). They found that 57% of the children had ADHD, with most (74%) having the inattentive type. The study also noted that the average length of their seizures was about 7.1 seconds, with some lasting as long as 38 seconds. Who this helps: This research benefits doctors and specialists treating children with epilepsy, as it highlights the need to also monitor for ADHD in these patients.

Plain English
This paper studied the challenges and options for treating children with acute myeloid leukemia (AML) who have relapsed, meaning their cancer returned after treatment. It found that while there are new targeted therapies being developed and international collaboration is improving access to these treatments, many children still face significant hurdles due to a lack of available clinical trials and the difficulty of getting drugs approved for young patients. This matters because finding effective treatments can lead to better outcomes for these children, especially with approaches like second stem cell transplants that can offer a chance for a cure. Who this helps: This research benefits patients with relapsed pediatric AML, their families, and healthcare providers involved in their treatment.

Plain English
This study looked at four patients in Kerala, India, who had skin infections caused by a bacterium called Mycobacterium marinum, which is usually found in water. The researchers highlighted how challenging it can be to diagnose this infection because it often gets mistaken for other skin problems. They emphasized the need for doctors to be alert to the possibility of M. marinum infections and reviewed the treatment options available. Who this helps: This benefits doctors and patients experiencing unexplained skin infections.

Plain English
This research looked at how well patients with severe aplastic anemia recover after receiving a bone marrow transplant from an unrelated donor, using different doses of a chemotherapy drug called cyclophosphamide. The study found that using a lower dose of 50 mg/kg showed good results, with an 8-year survival rate of 85%, while the slightly higher dose of 100 mg/kg had a survival rate of 75.6%. This matters because it helps identify safer and effective treatment options for patients undergoing transplants, particularly since many older patients face higher risks. Who this helps: This benefits patients with severe aplastic anemia and their doctors by providing clearer guidance on transplantation options.

Plain English
This study examined a 52-year-old man with advanced non-small-cell lung cancer who had a specific genetic change known as the ROS1 fusion gene. After not responding well to standard chemotherapy, he experienced an outstanding and lasting improvement using a drug called crizotinib, with his cancer not worsening for 94 months and showing no signs on scans. This finding highlights how important it is to test for specific genetic changes in cancer, as targeted therapies like crizotinib can lead to much better outcomes for patients. Who this helps: Patients with ROS1-positive advanced non-small-cell lung cancer.

Plain English
This study looked at how to determine which children with sickle cell disease can participate in a specific clinical trial for a type of stem cell transplant. Initially, only children who had experienced a full stroke were allowed to join, but the criteria were later expanded to also include those with silent strokes and other serious health issues, allowing a total of 18 children into the trial. This is important because it helps create a clear and fair process for including more children with sickle cell disease, potentially improving their chances for curative treatments. Who this helps: This helps children with sickle cell disease and their families.

Plain English
This study looked at how to enroll participants in a trial comparing bone marrow transplantation (BMT) to standard care for adolescents and young adults with sickle cell disease. Of the target 200 participants, only 138 enrolled because many could not find suitable donors, faced insurance challenges, or were discouraged by the standard treatment option. These findings highlight the barriers to getting patients into clinical trials, which is important for developing effective treatments for sickle cell disease. Who this helps: Patients with sickle cell disease and researchers planning future clinical trials.

Plain English
This study looked at the risk of developing new cancers after undergoing a stem cell transplant for sickle cell disease. Out of 1,096 patients studied from 1991 to 2016, 22 were found to develop secondary cancers, most commonly leukemia or myelodysplastic syndromes (15 cases) and solid tumors (7 cases). It was found that patients who received less intense treatment regimens were significantly more likely to develop leukemia/MDS or any secondary cancer, with a 10-year incidence of 1.7% and 2.4%, respectively. Who this helps: This information helps doctors and patients by guiding treatment decisions during stem cell transplants for sickle cell disease.

Plain English
This study looked at patients with aplastic anaemia who received bone marrow transplants from their identical twins to understand what causes the disease. Out of 59 patients, those who had a transplant without special preparation had only a 18% recovery rate, while 100% of those who were properly prepared beforehand recovered their bone marrow function. This finding is important because it suggests that most cases of aplastic anaemia are related to the immune system attacking the bone marrow and that better outcomes can be achieved with pre-transplant conditioning. Who this helps: This helps patients with aplastic anaemia and their doctors.

Plain English
Researchers studied how well patients from different racial and ethnic backgrounds are doing after receiving blood and bone marrow transplants, especially when using donors that don’t perfectly match. They found that between 2009 and 2020, more patients from diverse backgrounds received these transplants, particularly using mismatched and haploidentical donors, and that survival rates have improved significantly in recent years. However, the main issue remains that many patients still die from their disease returning after treatment. Who this helps: This information is valuable for patients needing transplants, as well as doctors treating them.

Plain English
This study looked at how the amount of a specific type of blood cell (CD34 cells) given during a stem cell transplant affects recovery outcomes in children with brain tumors. Researchers found that children who received more than 3.6 million CD34 cells per kilogram had better chances of survival and staying cancer-free compared to those who got less—specifically, they had improved overall survival and progression-free survival rates with fewer relapses. Importantly, giving a higher dose of CD34 cells did not increase the risk of serious complications. Who this helps: This research benefits pediatric patients with central nervous system tumors and their doctors.

Plain English
This study investigated how levels of a drug called alemtuzumab and certain inflammatory markers could predict the success of a specific type of stem cell transplant in patients with blood disorders. They found that patients with lower levels of alemtuzumab (0.32 µg/mL or less) had a much lower chance of mixed chimerism (only 14.3% compared to 90.9% for higher levels), which is when the patient’s body doesn't fully accept the donor cells. Additionally, those with lower levels of a marker named CXCL9 were less likely to experience problems with their graft, showing a strong link between these levels and transplant success. Who this helps: This research benefits patients undergoing stem cell transplants for conditions like hemophagocytic lymphohistiocytosis and other immune disorders.

Plain English
This study looked at two types of bone marrow transplants for patients with serious blood cancers: one using umbilical cord blood and the other using bone marrow from a relative. They found that after five years, 42% of patients receiving bone marrow from a related donor survived compared to 36% for those getting umbilical cord blood. Over 20 years, the relative donor method is expected to be better and more cost-effective for patients under 65, while it’s less expensive and still effective for those 65 and older. Who this helps: This helps patients with high-risk leukemia and lymphoma, as well as their doctors in making treatment decisions.

Plain English
This study looked at patients with severe aplastic anemia who survived at least one year after receiving either immunosuppressive therapy or a stem cell transplant. The researchers found that mortality rates for these patients decreased over time; those who had immunosuppressive treatment could expect to have similar life expectancy to the general population after five years, while those who had a stem cell transplant saw similar outcomes after ten years. This is important because it shows that long-term survival rates for these patients have improved, indicating better outcomes from these treatments. Who this helps: Patients with severe aplastic anemia and their healthcare providers.

Plain English
This study focused on pemphigus, a serious autoimmune skin disorder, examining how well two methods—immunohistochemistry (IHC) and antibody tests—correlate with illness severity in patients. Among 49 studied cases, all pemphigus foliaceus patients scored low for a specific protein (dsg 1), while most pemphigus vulgaris patients scored low for another (dsg 3). Additionally, both antibody levels linked closely with disease severity, indicating that these diagnostic methods can effectively track disease progression. Who this helps: This research benefits patients with pemphigus and their doctors by improving diagnosis and treatment monitoring.

Plain English
This study looked at how researchers choose and evaluate the outcomes (or endpoints) in studies about blood disorders. It found that selecting the right outcomes, like treatment effectiveness and patient survival, is crucial for understanding how well the treatments work. The paper emphasizes the need for guidelines on these selections to improve future clinical trials. Who this helps: This benefits researchers designing clinical trials for blood disease treatments.

Plain English
A young man with a history of alcohol-related pancreatitis had high fevers, severe joint pain, and painful skin nodules for two months. Doctors found that his condition involved fat dying under the skin and other complicated issues related to his pancreas, but typical medications didn’t work. After a surgery to drain his pancreas, all his symptoms disappeared, showing that this condition, called PPP syndrome, can be effectively treated with the right intervention. Who this helps: This helps patients experiencing pancreatitis-related complications and their doctors in diagnosing and treating similar conditions.

Plain English
This study looked at skin issues caused by a type of diabetes medication called DPP-4 inhibitors in 18 patients over a span of four years. They found that 66.6% of these patients experienced a specific condition known as bullous pemphigoid, while others had different skin problems. Notably, 61.1% of the patients felt better after stopping the medication, with some even seeing complete healing within six months. Who this helps: This information can benefit patients using DPP-4 inhibitors and their doctors by raising awareness of potential skin side effects and treatment options.

Plain English
This study looked at a patient with a skin condition called generalized granuloma annulare, which involves raised, ring-shaped patches on the skin that had lasted for 10 months. Remarkably, these lesions began to clear up just one week after a biopsy was performed, without any other treatment. This finding is important because it highlights a unique response where the act of taking a skin sample seems to have triggered healing in the surrounding areas. Who this helps: This benefits patients with granuloma annulare and doctors treating skin conditions.

Plain English
This study looked at the long-term survival of patients with sickle cell disease who underwent a specific treatment called hematopoietic cell transplant. Researchers found that out of nearly 1,000 patients, those who survived at least 7 years after the transplant had a 12-year survival probability of 97%. However, patients who were older or received transplants from non-sibling donors had a higher risk of dying after the transplant, highlighting the importance of donor matching and patient age. Who this helps: This research benefits patients with sickle cell disease and their healthcare providers by providing valuable information on the risks and outcomes of treatment.

Plain English
This study looked at a very rare type of tumor called extramedullary plasmacytoma (EMP) that occurred without the usual presence of multiple myeloma. The researchers presented a case where a patient had multiple tumors in unusual places like the nasal cavity, testis, and skin, and he was treated successfully with a specific chemotherapy regimen. Remarkably, this patient has been cancer-free for 29 months, longer than any of the previous cases documented. Who this helps: This information benefits doctors and patients facing rare cases of extramedullary plasmacytoma.

Plain English
This study looked at a patient who developed extensive skin lightening (vitiligo) as a side effect of a breast cancer drug called ribociclib. The researchers examined the skin changes and found that ribociclib might affect certain skin cells, leading to this condition. Understanding these effects is important because it helps doctors manage skin issues in patients taking ribociclib. Who this helps: This helps patients undergoing treatment for breast cancer.

Plain English
This study examined how a transplantation center’s experience with different types of stem cell donations—double umbilical cord blood or haploidentical bone marrow—affected patient outcomes after transplants. The researchers found that patients treated at centers experienced with haploidentical bone marrow had lower overall mortality rates compared to those treated at centers focused on cord blood donations, but only in haplo-BM centers. Specifically, the study showed a 2.56 times higher risk of death for patients in cord blood centers compared to those in haplo-BM centers, although experience level affected outcomes in other ways too. Who this helps: This research benefits patients undergoing stem cell transplants by highlighting the importance of center experience in improving survival rates.

Plain English
The study looked at how Kerala State in India responded to the Covid-19 pandemic with a focus on women’s needs. It found that during the pandemic, Kerala provided specific support to women, including cash assistance, job opportunities, free food, and zero-interest loans. This approach helped address issues like increased domestic violence and mental health problems, illustrating how important it is for health policies to consider gender. Who this helps: This helps women and families in Kerala who faced added challenges during the pandemic.

Plain English
This study looked at how hematopoietic cell transplantation (HCT) is used in the U.S. and its results, especially for adolescents and young adults (AYA). It found that survival rates for AYA patients have significantly improved, with major advancements seen between 2000 and 2019, and that AYA patients generally do better than older adults but have worse outcomes for certain types of leukemia compared to younger kids. This information is important because it highlights the evolving treatment success and guides healthcare practices for younger patients. Who this helps: This benefits patients, particularly adolescents and young adults facing hematological conditions.

Plain English
This study examined the effectiveness of haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anemia, a condition where the body fails to produce enough blood cells. Out of 31 patients who received the transplant, 24 (77%) were still alive one year later, leading to an overall survival rate of 81%. This is significant as it shows a promising option for patients who have difficulty finding a matched donor, potentially helping to standardize treatment across different patient populations. Who this helps: Patients with severe aplastic anemia who do not have a matched bone marrow donor.